Camurus AB (CAMX.ST) stock: key figures, P/E, revenue and dividend
Health Care · Sweden · ISIN SE0007692850
Camurus AB financials
| Fiscal year | 2024 | 2025 |
|---|---|---|
| Revenue | 1.87 bn SEK | 2.27 bn SEK |
| Gross profit | 1.74 bn SEK | 2.11 bn SEK |
| Operating income | 463.63 m SEK | 885.16 m SEK |
| EBIT | 469.00 m SEK | 884.00 m SEK |
| Net income | 428.00 m SEK | 735.00 m SEK |
| Diluted EPS – continuing operations | 7.15 SEK | 12.20 SEK |
Full history since 2011, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Camurus AB
Camurus AB (publ), a biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia. The company offers Buvidal, a buprenorphine injection for the treatment of opioid dependence and chronic pain; and Brixadi to treat opioid use disorder. It also provides CAM2038 for the treatment of chronic pain; CAM2029, which completed phase III clinical trials for the treatment of acromegaly, and is under phase III clinical trials to treat gastroenteropancreatic neuroendocrine tumors, as well as in phase II clinical trial to treat polycystic liver diseases; and CAM2043 for the treatment of pulmonary arterial hypertension, as well as in phase II clinical trial to treat Raynaud's phenomenon. In addition, the company is developing CAM2032, which is in phase II clinical trials for the treatment of prostate cancer; CAM4072 that is in phase III clinical trials for the treatment of genetic obesity disorders; CAM2056 that is in phase I clinical trials for the treatment of metabolic diseases; CAM4071, which is in phase I clinical trials for the treatment of endocrine disorder; and CAM2047 that is in phase 1 clinical trial for the treatment of chemotherapy-induced nausea and vomiting. It has strategic partnerships with Braeburn Pharmaceuticals to develop CAM2038 for the treatment of opioid use disorder; Rhythm Pharmaceuticals Inc. to develop CAM4072 for the treatment of a range of rare genetic disorders of obesity; Gubra A/S to develop long-acting therapeutic option for the treatment of hypoparathyroidism; NewBridge Pharmaceuticals; and Eli Lilly for the development of long-acting incretin medicines based on FluidCrystal technology. Camurus AB (publ) was founded in 1991 and is headquartered in Lund, Sweden.
More stocks
- MYR GROUP INC. (MYRG)
- Jiangsu Yuyue Medical Equipment & Supply Co Ltd (002223.SZ)
- Sopra Steria Group SA (SOP.PA)
- Sime Darby Bhd (4197.KL)
- Titan SA (TITC.BR)
- Toyo Tire Corp (5105.T)
- Asmodee Group AB (ASMDEE B.ST)
- Societe Anonyme des Bains de Mer et du Cercle des Etrangers a Monaco SA (BAIN.PA)
- Kingdee International Software Group Co Ltd (268.HK)
- China Film Co Ltd (600977.SS)
- Do-Fluoride Chemicals Co Ltd (002407.SZ)
- Kansai Paint Co Ltd (4613.T)
Not investment advice. All data without warranty, price as of 22.10.2026. Details in the risk notice.